^
    Back
    Association details:
    Biomarker:EGFR exon 19 deletion + VEGFA-L
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    erlotinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Transl Lung Cancer Res
    Title:

    Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR+non-small-cell lung cancer

    Published date:
    05/30/2023
    Excerpt:
    Eligible patients had histologically and/or cytologically confirmed stage IIIB/IV or postoperative recurrent non-squamous NSCLC with an activating EGFR mutation (either exon 19 deletion or L858R mutation)....Low pVEGFA levels related to better outcomes with EB, interaction P=0.033.
    DOI:
    10.21037/tlcr-22-632